Literature DB >> 28086011

Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease.

Elise A Weamer1, Mary Ann A DeMichele-Sweet2, Yona K Cloonan3, Oscar L Lopez1,2, Robert A Sweet4,1,2,5.   

Abstract

OBJECTIVE: To estimate the incidence of psychotic symptoms in Alzheimer's disease.
METHODS: The study consists of 776 elderly subjects presenting to the Alzheimer Disease Research Center at the University of Pittsburgh (Pittsburgh, Pennsylvania) between May 9, 2000, and August 19, 2014. All participants were diagnosed with mild cognitive impairment (National Institute on Aging-Alzheimer's Association workgroup criteria) or possible or probable Alzheimer's disease (National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria) and were without psychosis at entry. Psychotic symptoms were evaluated using the Consortium to Establish a Registry for Alzheimer's Disease Behavioral Rating Scale every 6 months. One-, 3- and 5-year cumulative incidences of psychosis were calculated.
RESULTS: The 1-year psychosis incidence was 10% (95% CI, 8%-12%), and this annual rate remained remarkably consistent at 3 and 5 years. Psychosis incidence was related to cognitive status at all time points. However, the incidence rate reached a plateau during the disease course. Cumulative psychosis incidence at 5 years was 61% (95% CI, 52%-69%) in individuals with moderate to severe Alzheimer's disease, not statistically significantly different from the cumulative incidence at 3 years in this group, which was 48% (95% CI, 40%-55%) or from the 5-year incidence in individuals who entered the study with mild Alzheimer's disease, which was 48% (95% CI, 41%-56%).
CONCLUSIONS: Psychosis in Alzheimer's disease has been associated with a number of adverse clinical outcomes. We provide estimates of the risk of psychosis onset within clinically defined subgroups of individuals, a tool clinicians can use in treatment planning. Anticipating which subjects are at high risk for psychosis and the poor outcomes associated with it can help with family education and support decisions to implement nonpharmacologic strategies that may reduce or prevent symptoms. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 28086011      PMCID: PMC5372698          DOI: 10.4088/JCP.15m10617

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  45 in total

1.  When do we need competing risks methods for survival analysis in nephrology?

Authors:  Marlies Noordzij; Karen Leffondré; Karlijn J van Stralen; Carmine Zoccali; Friedo W Dekker; Kitty J Jager
Journal:  Nephrol Dial Transplant       Date:  2013-08-24       Impact factor: 5.992

2.  The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up.

Authors:  C G Ballard; J T O'Brien; A G Swann; P Thompson; D Neill; I G McKeith
Journal:  J Clin Psychiatry       Date:  2001-01       Impact factor: 4.384

3.  Delusions and hallucinations are associated with worse outcome in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Marilyn Albert; Georgios Hadjigeorgiou; Alexandros Papadimitriou; Bruno Dubois; Maria Sarazin; Davangere Devanand; Lawrence Honig; Karen Marder; Karen Bell; Domonick Wegesin; Deborah Blacker; Yaakov Stern
Journal:  Arch Neurol       Date:  2005-10

4.  Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates.

Authors:  M M Bassiony; M S Steinberg; A Warren; A Rosenblatt; A S Baker; C G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2000-02       Impact factor: 3.485

Review 5.  Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003.

Authors:  Susan A Ropacki; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2005-11       Impact factor: 18.112

6.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

7.  Trajectories of cognitive decline in Alzheimer's disease.

Authors:  Patricia A Wilkosz; Howard J Seltman; Bernie Devlin; Elise A Weamer; Oscar L Lopez; Steven T DeKosky; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2009-09-28       Impact factor: 3.878

8.  A Bayesian model of psychosis symptom trajectory in Alzheimer's disease.

Authors:  Howard J Seltman; Shaina Mitchell; Robert A Sweet
Journal:  Int J Geriatr Psychiatry       Date:  2015-07-27       Impact factor: 3.485

9.  Non-pharmacological treatment reducing not only behavioral symptoms, but also psychotic symptoms of older adults with dementia: a prospective cohort study in Taiwan.

Authors:  Rue-Chuan Chen; Chien-Liang Liu; Ming-Hsien Lin; Li-Ning Peng; Liang-Yu Chen; Li-Kuo Liu; Liang-Kung Chen
Journal:  Geriatr Gerontol Int       Date:  2013-08-01       Impact factor: 2.730

10.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

Authors:  C Steele; B Rovner; G A Chase; M Folstein
Journal:  Am J Psychiatry       Date:  1990-08       Impact factor: 18.112

View more
  11 in total

1.  Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease.

Authors:  Josh M Krivinko; Susan L Erickson; Ying Ding; Zhe Sun; Peter Penzes; Matthew L MacDonald; Nathan A Yates; Milos D Ikonomovic; Oscar L Lopez; Robert A Sweet; Julia Kofler
Journal:  Am J Psychiatry       Date:  2018-07-19       Impact factor: 18.112

2.  Neuropsychiatric Symptoms and Risk Factors in Mild Cognitive Impairment: A Cohort Investigation of Elderly Patients.

Authors:  A-N Yang; X-L Wang; H-R Rui; H Luo; M Pang; X-M Dou
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

3.  Koro Delusion in Mild Cognitive Impairment Due to Alzheimer's Disease.

Authors:  Michael Tau; Arjun V Masurkar
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2019-09-18       Impact factor: 2.198

4.  Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients.

Authors:  Lirong Wang; Jian Ying; Peihao Fan; Elise A Weamer; Mary Ann A DeMichele-Sweet; Oscar L Lopez; Julia K Kofler; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-27       Impact factor: 4.105

Review 5.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

6.  Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease.

Authors:  Riccardo Manca; Jose Manuel Valera-Bermejo; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-13       Impact factor: 5.270

7.  Genetic risk for schizophrenia and psychosis in Alzheimer disease.

Authors:  M A A DeMichele-Sweet; E A Weamer; L Klei; D T Vrana; D J Hollingshead; H J Seltman; R Sims; T Foroud; I Hernandez; S Moreno-Grau; L Tárraga; M Boada; A Ruiz; J Williams; R Mayeux; O L Lopez; E L Sibille; M I Kamboh; B Devlin; R A Sweet
Journal:  Mol Psychiatry       Date:  2017-05-02       Impact factor: 15.992

8.  Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease.

Authors:  Corinne E Fischer; Winnie Qian; Tom A Schweizer; Zahinoor Ismail; Eric E Smith; Colleen P Millikin; David G Munoz
Journal:  Alzheimers Dement (N Y)       Date:  2017-06-21

Review 9.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024

10.  Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.

Authors:  Mary Ann A DeMichele-Sweet; Lambertus Klei; Byron Creese; Janet C Harwood; Elise A Weamer; Lora McClain; Rebecca Sims; Isabel Hernandez; Sonia Moreno-Grau; Lluís Tárraga; Mercè Boada; Emilio Alarcón-Martín; Sergi Valero; Yushi Liu; Basavaraj Hooli; Dag Aarsland; Geir Selbaek; Sverre Bergh; Arvid Rongve; Ingvild Saltvedt; Håvard K Skjellegrind; Bo Engdahl; Eystein Stordal; Ole A Andreassen; Srdjan Djurovic; Lavinia Athanasiu; Davide Seripa; Barbara Borroni; Diego Albani; Gianluigi Forloni; Patrizia Mecocci; Alessandro Serretti; Diana De Ronchi; Antonis Politis; Julie Williams; Richard Mayeux; Tatiana Foroud; Agustin Ruiz; Clive Ballard; Peter Holmans; Oscar L Lopez; M Ilyas Kamboh; Bernie Devlin; Robert A Sweet
Journal:  Mol Psychiatry       Date:  2021-06-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.